AstraZeneca PLC (AZN)vsSupernus Pharmaceuticals Inc (SUPN)
AZN
AstraZeneca PLC
$185.95
-0.79%
HEALTHCARE · Cap: $282.69B
SUPN
Supernus Pharmaceuticals Inc
$44.75
+0.11%
HEALTHCARE · Cap: $2.58B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 7680% more annual revenue ($60.44B vs $776.83M). AZN leads profitability with a 17.2% profit margin vs -3.7%. AZN appears more attractively valued with a PEG of 1.39. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
SUPN
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Intrinsic value data unavailable for SUPN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Revenue surging 38.6% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Weak financial health signals
ROE of -2.8% — below average capital efficiency
Currently unprofitable
Operating margin of -3.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : SUPN
The strongest argument for SUPN centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 38.6% demonstrates continued momentum. PEG of 1.47 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : SUPN
The primary concerns for SUPN are Piotroski F-Score, Return on Equity, Profit Margin.
Key Dynamics to Monitor
AZN profiles as a mature stock while SUPN is a hypergrowth play — different risk/reward profiles.
SUPN carries more volatility with a beta of 0.54 — expect wider price swings.
SUPN is growing revenue faster at 38.6% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 52/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Supernus Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of diseases of the central nervous system in the United States. The company is headquartered in Rockville, Maryland.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?